At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 63 enrolled
Drug / intervention
bevacizumab +1 moredrug
Likely dose
bevacizumab 1.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does a New Add on (or Adjunctive) Therapy Used in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
In Brief
A Phase 3 clinical trial evaluating bevacizumab and balanced salt solution for Glaucoma. Completed, enrolled 63 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionJan 2012
TodayJul 2026
First PostedFeb 27, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.3 years ago
Interventions
bevacizumabdrug
1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
balanced salt solutionother
0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure